세계의 월경통 치료 시장 : 유형별, 치료법별, 유통 채널별-기회 분석 및 산업 예측(2021-2031년)

Menstrual cramps are strong cramping pains in lower abdomen. Many women experience menstrual pains shortly before and throughout their periods. It can be caused by conditions such as endometriosis or uterine fibroids. Symptoms of menstrual cramps include throbbing or cramping pain in the lower abdomen, and pain in lower back and thighs. Some women also experience nausea, loose stools, headache, and dizziness.

The growth of global menstrual cramps treatment market is majorly driven by increase in demand for menstrual cramps treatment, owing to rise in cases of menstrual pain in women. In addition, growing awareness of menstrual cramps treatment further drive growth of the menstrual cramps treatment market. However, lack of knowledge regarding menstrual cramps treatment and side effects of menstrual cramps drugs such as nausea, constipation and vomiting hinders the market growth. Conversely, growth opportunities in emerging markets and surge in expenditure worldwide are anticipated to provide lucrative opportunities to the market players.

The menstrual cramps treatment market is segmented into type, treatment, distribution channel, and region. On the basis of type, the market is categorized into primary dysmenorrhea and secondary dysmenorrhea. On the basis of treatment, the market is segregated into non-steroidal anti-inflammatory drugs and hormonal therapy. On the basis of distribution channel, the market is classified into hospital pharmacies and drug stores & retail pharmacies and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major Key players that operate in the global menstrual cramps treatment market are Abbott Laboratories, AbbVie Inc., Bayer AG, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson Private Limited, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, and Torrent Pharmaceuticals.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the menstrual cramps treatment market analysis from 2021 to 2031 to identify the prevailing menstrual cramps treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the menstrual cramps treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global menstrual cramps treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

• Primary Dysmenorrhea
• Secondary Dysmenorrhea

By Treatment

• Non-steroidal Anti-inflammatory Drugs
• Hormonal Therapy

By Distribution Channel

• Hospital Pharmacies
• Drug stores and Retail Pharmacies
• Online Providers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
• Key Market Players
  • AbbVie Inc.
  • Bayer AG
  • Johnson and Johnson
  • Taj Pharmaceuticals Limited
  • Torrent Pharmaceuticals Ltd.
  • Abbott Laboratories
  • Dr. Reddy's Laboratories Ltd.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Primary Dysmenorrhea
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market share analysis by country
• 4.3 Secondary Dysmenorrhea
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market share analysis by country

CHAPTER 5: MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Non-steroidal Anti-inflammatory Drugs
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market share analysis by country
• 5.3 Hormonal Therapy
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market share analysis by country

CHAPTER 6: MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Hospital Pharmacies
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market share analysis by country
• 6.3 Drug stores and Retail Pharmacies
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market share analysis by country
• 6.4 Online Providers
  • 6.4.1 Key market trends, growth factors and opportunities
  • 6.4.2 Market size and forecast, by region
  • 6.4.3 Market share analysis by country

CHAPTER 7: MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Type
  • 7.2.3 North America Market size and forecast, by Treatment
  • 7.2.4 North America Market size and forecast, by Distribution Channel
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Key market trends, growth factors and opportunities
    • 7.2.5.1.2 Market size and forecast, by Type
    • 7.2.5.1.3 Market size and forecast, by Treatment
    • 7.2.5.1.4 Market size and forecast, by Distribution Channel
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Key market trends, growth factors and opportunities
    • 7.2.5.2.2 Market size and forecast, by Type
    • 7.2.5.2.3 Market size and forecast, by Treatment
    • 7.2.5.2.4 Market size and forecast, by Distribution Channel
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Key market trends, growth factors and opportunities
    • 7.2.5.3.2 Market size and forecast, by Type
    • 7.2.5.3.3 Market size and forecast, by Treatment
    • 7.2.5.3.4 Market size and forecast, by Distribution Channel
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Type
  • 7.3.3 Europe Market size and forecast, by Treatment
  • 7.3.4 Europe Market size and forecast, by Distribution Channel
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Key market trends, growth factors and opportunities
    • 7.3.5.1.2 Market size and forecast, by Type
    • 7.3.5.1.3 Market size and forecast, by Treatment
    • 7.3.5.1.4 Market size and forecast, by Distribution Channel
    • 7.3.5.2 France
    • 7.3.5.2.1 Key market trends, growth factors and opportunities
    • 7.3.5.2.2 Market size and forecast, by Type
    • 7.3.5.2.3 Market size and forecast, by Treatment
    • 7.3.5.2.4 Market size and forecast, by Distribution Channel
    • 7.3.5.3 UK
    • 7.3.5.3.1 Key market trends, growth factors and opportunities
    • 7.3.5.3.2 Market size and forecast, by Type
    • 7.3.5.3.3 Market size and forecast, by Treatment
    • 7.3.5.3.4 Market size and forecast, by Distribution Channel
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Key market trends, growth factors and opportunities
    • 7.3.5.4.2 Market size and forecast, by Type
    • 7.3.5.4.3 Market size and forecast, by Treatment
    • 7.3.5.4.4 Market size and forecast, by Distribution Channel
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Key market trends, growth factors and opportunities
    • 7.3.5.5.2 Market size and forecast, by Type
    • 7.3.5.5.3 Market size and forecast, by Treatment
    • 7.3.5.5.4 Market size and forecast, by Distribution Channel
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Key market trends, growth factors and opportunities
    • 7.3.5.6.2 Market size and forecast, by Type
    • 7.3.5.6.3 Market size and forecast, by Treatment
    • 7.3.5.6.4 Market size and forecast, by Distribution Channel
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Type
  • 7.4.3 Asia-Pacific Market size and forecast, by Treatment
  • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Key market trends, growth factors and opportunities
    • 7.4.5.1.2 Market size and forecast, by Type
    • 7.4.5.1.3 Market size and forecast, by Treatment
    • 7.4.5.1.4 Market size and forecast, by Distribution Channel
    • 7.4.5.2 China
    • 7.4.5.2.1 Key market trends, growth factors and opportunities
    • 7.4.5.2.2 Market size and forecast, by Type
    • 7.4.5.2.3 Market size and forecast, by Treatment
    • 7.4.5.2.4 Market size and forecast, by Distribution Channel
    • 7.4.5.3 India
    • 7.4.5.3.1 Key market trends, growth factors and opportunities
    • 7.4.5.3.2 Market size and forecast, by Type
    • 7.4.5.3.3 Market size and forecast, by Treatment
    • 7.4.5.3.4 Market size and forecast, by Distribution Channel
    • 7.4.5.4 Australia
    • 7.4.5.4.1 Key market trends, growth factors and opportunities
    • 7.4.5.4.2 Market size and forecast, by Type
    • 7.4.5.4.3 Market size and forecast, by Treatment
    • 7.4.5.4.4 Market size and forecast, by Distribution Channel
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Key market trends, growth factors and opportunities
    • 7.4.5.5.2 Market size and forecast, by Type
    • 7.4.5.5.3 Market size and forecast, by Treatment
    • 7.4.5.5.4 Market size and forecast, by Distribution Channel
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Key market trends, growth factors and opportunities
    • 7.4.5.6.2 Market size and forecast, by Type
    • 7.4.5.6.3 Market size and forecast, by Treatment
    • 7.4.5.6.4 Market size and forecast, by Distribution Channel
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Type
  • 7.5.3 LAMEA Market size and forecast, by Treatment
  • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Key market trends, growth factors and opportunities
    • 7.5.5.1.2 Market size and forecast, by Type
    • 7.5.5.1.3 Market size and forecast, by Treatment
    • 7.5.5.1.4 Market size and forecast, by Distribution Channel
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Key market trends, growth factors and opportunities
    • 7.5.5.2.2 Market size and forecast, by Type
    • 7.5.5.2.3 Market size and forecast, by Treatment
    • 7.5.5.2.4 Market size and forecast, by Distribution Channel
    • 7.5.5.3 South Africa
    • 7.5.5.3.1 Key market trends, growth factors and opportunities
    • 7.5.5.3.2 Market size and forecast, by Type
    • 7.5.5.3.3 Market size and forecast, by Treatment
    • 7.5.5.3.4 Market size and forecast, by Distribution Channel
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Key market trends, growth factors and opportunities
    • 7.5.5.4.2 Market size and forecast, by Type
    • 7.5.5.4.3 Market size and forecast, by Treatment
    • 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 AbbVie Inc.
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments
• 9.2 Bayer AG
  • 9.2.1 Company overview
  • 9.2.2 Company snapshot
  • 9.2.3 Operating business segments
  • 9.2.4 Product portfolio
  • 9.2.5 Business performance
  • 9.2.6 Key strategic moves and developments
• 9.3 Johnson and Johnson
  • 9.3.1 Company overview
  • 9.3.2 Company snapshot
  • 9.3.3 Operating business segments
  • 9.3.4 Product portfolio
  • 9.3.5 Business performance
  • 9.3.6 Key strategic moves and developments
• 9.4 Taj Pharmaceuticals Limited
  • 9.4.1 Company overview
  • 9.4.2 Company snapshot
  • 9.4.3 Operating business segments
  • 9.4.4 Product portfolio
  • 9.4.5 Business performance
  • 9.4.6 Key strategic moves and developments
• 9.5 Torrent Pharmaceuticals Ltd.
  • 9.5.1 Company overview
  • 9.5.2 Company snapshot
  • 9.5.3 Operating business segments
  • 9.5.4 Product portfolio
  • 9.5.5 Business performance
  • 9.5.6 Key strategic moves and developments
• 9.6 Abbott Laboratories
  • 9.6.1 Company overview
  • 9.6.2 Company snapshot
  • 9.6.3 Operating business segments
  • 9.6.4 Product portfolio
  • 9.6.5 Business performance
  • 9.6.6 Key strategic moves and developments
• 9.7 Dr. Reddy's Laboratories Ltd.
  • 9.7.1 Company overview
  • 9.7.2 Company snapshot
  • 9.7.3 Operating business segments
  • 9.7.4 Product portfolio
  • 9.7.5 Business performance
  • 9.7.6 Key strategic moves and developments
• 9.8 GlaxoSmithKline plc
  • 9.8.1 Company overview
  • 9.8.2 Company snapshot
  • 9.8.3 Operating business segments
  • 9.8.4 Product portfolio
  • 9.8.5 Business performance
  • 9.8.6 Key strategic moves and developments
• 9.9 Pfizer Inc.
  • 9.9.1 Company overview
  • 9.9.2 Company snapshot
  • 9.9.3 Operating business segments
  • 9.9.4 Product portfolio
  • 9.9.5 Business performance
  • 9.9.6 Key strategic moves and developments
• 9.10 Sun Pharmaceutical Industries Ltd.
  • 9.10.1 Company overview
  • 9.10.2 Company snapshot
  • 9.10.3 Operating business segments
  • 9.10.4 Product portfolio
  • 9.10.5 Business performance
  • 9.10.6 Key strategic moves and developments